Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study found that androgens decreased splenic macrophage FcgammaR expression and impaired the clearance of IgG-coated cells in an experimental guinea pig model.

This study retrospectively evaluated the effectiveness of off-label baricitinib in children with severe alopecia areata and found that 50% achieved treatment goals, though psychological effects were noted and laboratory abnormalities occurred in 42.86% of patients.

This study reports that using ascorbic acid or orlistat can significantly inhibit the metabolism of testosterone esters into malodorous metabolites by axillary bacteria, suggesting potential new deodorant applications.

In this study, maslinic acid applied topically was observed to stimulate hair growth in mice comparably to minoxidil, primarily activating pathways like Wnt/β-catenin, and suggesting a link between hair growth and cilia activity.

This study developed the mTurquoise2-Col4a1 mouse model and used fluorescent tagging of collagen IV to offer new insights into basement membrane dynamics during hair follicle budding, revealing that basement membranes are flexible and stable structures in developing skin tissue.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This case report describes the first confirmed instances of X-linked adrenomyeloneuropathy/adrenoleukodystrophy in two brothers from Bangladesh, noting their progressive neurological symptoms, MRI findings, and differing disease outcomes over several years of observation.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found that Smad4 is crucial for satellite cell amplification during skeletal muscle regeneration, with aged cells exhibiting less Smad4 and reduced regenerative capability in mice.

This study found that Dab2 conditional knockout mice experienced delayed hair follicle cycles and reduced hair follicle stem cell activity, suggesting Dab2's crucial role in regulating stem cell activation and anti-aging process in hair follicles.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This research suggests that the barley protein RACB supports cell polarity functions rather than interfering with immunity, as it aids nucleus positioning during fungal attack rather than affecting early immune responses.

This article proposes using the hallmarks of ageing and dysregulated microRNAs to create a molecular morbidity score that could improve prognostication and clinical trial inclusion for patients with multimorbidity.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

In a mouse model study, researchers observed that the absence of MCPIP1 in myeloid cells decreased susceptibility to chemically induced skin papillomas but caused significant hair loss and skin pigmentation changes, suggesting a role for MCPIP1 in skin carcinogenesis and follicle integrity.

This study found that high doses of TCB caused severe toxicity in cotton top marmoset monkeys, with clinical and histological changes similar to those in humans and other primates exposed to PCBs.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study found that a nutritional intervention in dogs can alleviate atopic dermatitis symptoms by modulating immune responses and altering skin microbiome composition, which includes reducing fungal diversity and the abundance of pathogenic species such as Malassezia pachydermatis.

This case report suggests that Malarone® may cause acute pancreatitis and alopecia in dogs, highlighting the need for careful monitoring of adverse reactions when using this drug in canine treatment.

This study found that ethyl acetate extract of Musa × pardisiaca L. leaves showed anticancer activity against cervical carcinoma and malignant melanoma in vitro.

In this study of pediatric melanocytic lesions, researchers at Massachusetts General Hospital observed no concurrent BAP1 loss and BRAFV600E positivity, characteristics of adult BIMT, suggesting that these tumors may develop at a later age rather than in childhood.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

This study found that HtrA2 inactivation in mnd2 mice is associated with delayed hair cycle phases and growth retardation of adipocytes, suggesting HtrA2's role in regulating adipogenesis-related hair growth.

In this prospective observational study of 96 dermatomyositis patients, 47 showed scalp involvement, with significant symptoms like scalp inflammation, itching, and hair loss linked to myositis-specific antibodies. The study highlighted unique dermatopathological features in the scalp and emphasized the considerable morbidity caused by scalp dermatomyositis.